Clinical usefulness of serum free light chains measurement in patients with multiple myeloma: comparative analysis of two different tests

Clinical usefulness of serum free light chains measurement in patients with multiple myeloma: comparative analysis of two different tests

<b>Introduction:</b> There are two commercially available tests for measurement of serum free light chains (sFLC) in multiple myeloma (MM) patients – Freelite and N Latex FLC. The aim of this study was to perform an assessment and direct comparison of the usefulness of the methods in rou...

Full description

Bibliographic Details
Main Authors:	Tadeusz Kubicki, Dominik Dytfeld, Aleksandra Baszczuk, Ewa Wysocka, Mieczysław Komarnicki, Krzysztof Lewandowski
Format:	Article
Language:	English
Published:	Index Copernicus International S.A. 2017-01-01
Series:	Postępy Higieny i Medycyny Doświadczalnej
Subjects:	serum free light chains Multiple Myeloma Freelite N Latex FLC comparison
Online Access:	http://phmd.pl/gicid/01.3001.0010.3788

Similar Items

Serum free light chain assays not total light chain assays are the standard of care to assess Monoclonal Gammopathies
by: Vania Tietsche de Moraes Hungria, et al.
Published: (2016-02-01)

Oligosecretory monoclonal gammopathy with renal involvement
by: L V Kozlovskaya, et al.
Published: (2016-12-01)

Current methods of diagnosis and monitoring of a systemic amyloidosis course
by: Vilen Vilevich Rameev, et al.
Published: (2011-08-01)

Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma
by: Punit Yadav, et al.
Published: (2018-07-01)

Evaluation of Correlation between Serum Free Light-Chain Assay and Bone Marrow Study in Multiple Myeloma Patients
by: Fatemeh Zamani, et al.
Published: (2021-07-01)

Serum free light chains and multiple myeloma: Is it time to extend their application?
by: Uros Markovic, et al.
Published: (2020-04-01)

Multiple myeloma: Detection of free monoclonal light chains by modified immunofixation electrophoresis with antisera against free light chains
by: Arfa, A., et al.
Published: (2021)

Multiple myeloma can be accurately diagnosed in acute kidney injury patients using a rapid serum free light chain test
by: Jennifer L. J. Heaney, et al.
Published: (2017-07-01)

Light Chain Escape Multiple Myeloma Complicated with Catastrophic Extramedullary Plasmacytoma Following Novel Agent Treatment
by: Yi-Ping Hung, et al.
Published: (2014-06-01)

Free light chains in patients with HIV: establishing local reference ranges and their association with stage of disease, chronic antigen stimulation and the effect of Haart
by: Germishuys, Jurie J.
Published: (2012)

Is the serum light chain quantification more sensitive than immunofixation in the diagnosis and follow up of patients with multiple myeloma ?
by: Guillermo José Ruiz-Argüelles
Published: (2014-08-01)

High serum level of endostatin in multiple myeloma at diagnosis but not in the plateau phase after treatment
by: Halina Urbanska-Rys, et al.
Published: (2003-01-01)

Immunoglobulin free light chains and GAGs mediate Multiple Myeloma Extracellular Vesicles uptake and secondary NfkB nuclear translocation
by: Giuseppe eDi Noto, et al.
Published: (2014-10-01)

ASSESSMENT OF THE RESIDUAL TUMOR IN PATIENTS WITH MULTIPLE MYELOMA BASED ON THE ANALYSIS OF THE FREE LIGHT CHAINS OF IMMUNOGLOBULINS IN BLOOD SERUM
by: T. A. Мitina, et al.
Published: (2016-02-01)

Analytical Criticalities Associated to Different Immunological Methods for Serum Free Light Chain Detection in Plasma Cell Dyscrasias: A Description of Particular Clinical Cases
by: Rocco Sabatino, et al.
Published: (2017-04-01)

Significance of serum protein electrophoresis in the detection of multiple myeloma: A diagnostic interpretation of patients with varied immunoglobulins
by: B S Nayak, et al.
Published: (2021-01-01)

The renal range of the κ/λ sFLC ratio: best strategy to evaluate multiple myeloma in patients with chronic kidney disease
by: Alícia Molina-Andújar, et al.
Published: (2020-03-01)

Ratio of involved/uninvolved immunoglobulin quantification by Hevylite™ assay: clinical and prognostic impact in multiple myeloma
by: Koulieris Efstathios, et al.
Published: (2012-04-01)

Novel renal replacement strategies for the elimination of serum free light chains in patients with kappa light chain nephropathy
by: Kleeberg L, et al.
Published: (2009-02-01)

Pharmacodynamic characteristics of velkeid efficacy in resistant and recurrent multiple myeloma: determination of free light chains of blood serum immunoglobulins
by: Anatoliy Konstantinovich Golenkov, et al.
Published: (2009-07-01)

Multiple Myeloma and Renal Failure
by: Patrizia Tosi, et al.
Published: (2015-03-01)

Free light chains of immunoglobulins in the diagnosis and prognosis of multiple myeloma
by: N. V. Lyubimova, et al.
Published: (2017-05-01)

Clinical recommendations for the measurement of serum free light chains and the emerging role of heavy/light chain pair analysis in the management of monoclonal gammopathies: When and how to use it?
by: Juana Jiménez Jiménez, et al.
Published: (2015-01-01)

Electrical characteristics of pure and contaminated latex serum
by: Huda Kosumphan, et al.
Published: (2018-04-01)

Cell Population Data and Serum Polyclonal Immunoglobulin Free Light Chains in the Assessment of COVID-19 Severity
by: Milena Małecka-Giełdowska, et al.
Published: (2021-07-01)

Early Normalization of Free Light Chains Predicts Better Outcomes in Patients with Multiple Myeloma
by: Rony Benson, et al.
Published: (2020-10-01)

Free light chains of immunoglobulin as a prognostic factor for some plasmaproliferative diseases
by: Mijušković Zoran, et al.
Published: (2011-01-01)

Difficulties evaluating hematological response in patients with multiple myeloma and dialysis - dependent renal impairment
by: I G Rekhtina, et al.
Published: (2019-07-01)

Combined proximal tubulopathy, crystal-storing histiocytosis, and cast nephropathy in a patient with light chain multiple myeloma
by: Chung-Kuan Wu, et al.
Published: (2017-05-01)

Prognostic value of unrelated atypical serum immunofixation patterns during Multiple Myeloma therapy
by: Guimarães Cristina, et al.
Published: (2012-06-01)

The importance of serum immunoglobulin free light chain assessment for predicting outcome in patients with newly diagnosed multiple myeloma in real clinical practice
by: N. V. Skvortsova, et al.
Published: (2020-10-01)

AN FLC-PSO ALGORITHM-CONTROLLED MOBILE ROBOT
by: Heru Suwoyo, et al.
Published: (2020-07-01)

Clinical profile of Saudi patients with multiple myeloma
by: Alanoud Abdulaziz Alhuqayl, et al.
Published: (2019-01-01)

Serum Free Light Chains Removal by HFR Hemodiafiltration in Patients with Multiple Myeloma and Acute Kidney Injury: a Case Series
by: Paolo Menè, et al.
Published: (2018-08-01)

Relationship of differences in immunoglobulin heavy/light chain pairs (HevyliteTM), selected laboratory parameters and stratification systems in different immunochemical types of multiple myeloma
by: Vlastimil Scudla, et al.
Published: (2016-03-01)

The importance of free light chains of immunoglobulins determination in serum
by: Čabarkapa Velibor, et al.
Published: (2007-01-01)

Skeletal Myopathy as the Initial Manifestation of Light Chain Multiple Myeloma
by: Mohamed Reda Belkhribchia, et al.
Published: (2020-11-01)

Light Chain Myeloma induced Severe Hypertriglyceridemia
by: Shafeeque Rahman, et al.
Published: (2017-03-01)

Endothelial activation and stress index (EASIX) is a reliable predictor for overall survival in patients with multiple myeloma
by: Ga-Young Song, et al.
Published: (2020-08-01)

The concurrence of light-chain deposition disease, AL-amyloidosis, and cast nephropathy in a patient with multiple myeloma
by: I G Rekhtina, et al.
Published: (2015-06-01)